Translational Biomarkers

Caberlotto, Laura
September 2011
Contract Pharma;Sep2011, Vol. 13 Issue 7, p106
Trade Publication
The article discusses aspects of translational biomarkers in the U.S. It highlights the importance of predictive biomarkers in preclinical drug discovery and development as well as in transnational activities. It cites the predictive biomarkers that facilitate the selection of lead compounds for development including markers of efficacy, safety and pharmacokinetics. It notes the essence of evaluating biomarkers because it allows companies to optimize safety and efficacy of their compounds.


Related Articles

  • Clinical progress for Predix depression drug.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p13 

    Reports on Predix Pharmaceuticals' conduction of further trials for its neuropsychiatric drug PRX-00023. Positive results for clinical assessments; Induction of surrogate biomarkers; Toleration of the drug in single and multiple doses; Evaluation of safety, pharmacokinetics and phamacodynamics.

  • High-Resolution Mass Spectrometry: An Ideal Premier Analytical Tool for Drug Metabolism Studies. Cen Xie; Xiaoyan Chen; Dafang Zhong; Kate Yu // LC-GC Europe;Sep2013, Vol. 26 Issue 9, p517 

    The article focuses on high resolution mass spectrometry which is an essential tool for research in drug metabolism. It discusses metabolism as one of the vital determinants of a drug's pharmacokinetic properties which affects the clearance and bioavailability of drug. It discusses innovations...

  • Biomarkers Move to Front Line of Drug Development. Keating, Sean // Drug Discovery & Development;Apr2005, Vol. 8 Issue 4, p41 

    Focuses on the growing interest of pharmaceutical companies on the use of biomarkers in drug development in the U.S. Emergence of groups that strategize on the process of discovering and implementing biomarkers; Significance of new technologies for biomarker discovery; Support of the Food and...

  • Building the Discovery Pipeline. Minkel, J. R. // Drug Discovery & Development;Dec2004, Vol. 7 Issue 12, p26 

    The article informs that reducing attrition and improving drug safety underlies pharmaceutical discovery efforts in 2004. Discovery continued its trend of becoming more targeted, rational, and information rich, with increased investment and interest in better understanding how drugs work and who...

  • BUZZ OVER Biomarker Discovery. Shaw, Gina // Drug Discovery & Development;Apr2006, Vol. 9 Issue 4, p38 

    The article looks at the potential of biomarkers to help the pharmaceutical industry work faster and more efficiently. The industry investment in biomarkers has risen 200 percent, a trend that is predicted to grow exponentially. Industries are under pressure to find objective, valid and...

  • Ultra High Throughput Analysis of Basic Drugs and Steroids Utilizing New 3 μm Column Technology. Evans, Bryan; Yazawa, Itaru; Qing Ping Han; Hayward, Mark J. // LC-GC North America;Feb2011 Supplement, Vol. 29, p19 

    The article presents a study on the use of Ultra High Performance Liquid Chromatography (UHPLC) and 3 micrometer particle columns in analyzing drugs in the U.S. in 2011. It notes the experiment using a UHPLC system which is equipped with Cadenza CD-C18 HT column. It reveals the importance of the...

  • Biomarkers and translational medicine. Bradley, Ian; Stewart, Keith // Pharmaceutical Technology Europe;Feb2007, Vol. 19 Issue 2, p58 

    The article focuses on the market implications of the growing capability of biomarker development translational medicine. Biomarkers are used by pharmaceutical companies in many drug development programs with preproof-of-concept biomarker studies allowing researchers to link results from animal...

  • The Push to Translational Medicine. Carini, Claudio // Pharma DD: Tracking Discovery & Development;Jan/Feb2007, Vol. 2 Issue 1, p15 

    The article focuses on the possible use of biochemical markers in Big Pharma. These tools are already being used in the human immunodeficiency virus (HIV) field. They may also be used in monitoring the safety and efficacy in drugs. However, there has not been much investment in biochemical...

  • Bench to bedside. Garattini, Silvio // European Journal of Clinical Pharmacology;Feb2006, Vol. 62 Issue 2, p89 

    The article comments on the views of Martin Wehling, who proposed that translational medicine could be a tool to bridge basic discoveries with practical applications, where innovation is scarce and costs of drug development is increasing in the pharmaceutical industry. He remarked that to...


Other Topics